Research and Development
PulmoHeal肺默癒®
Pulmonary fibrosis (PF) results from abnormal wound healing during ongoing injury and is characterized by the excessive accumulation of extracellular matrix (ECM) in and around inflamed or damaged tissue, which may impair the physiological function of the affected tissue and eventually lead to organ failure. There are many potential causes of pulmonary fibrosis, such as virus infection (covid-19, SARS-CoV and other viruses), acute respiratory distress syndrome (ARDS), autoimmune disease, cigarette smoking and so on. Taking interstitial lung disease (ILD) for example, the prevalence of ILD is estimated 76.0 per 100,000 people in Europe and 74.3 per 100,000 people in the USA. According to research, patients with ILD have a high probability of developing pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF), a specific form of chronic and progressive fibrosing interstitial pneumonia of unknown cause, is a common and typical type of pulmonary fibrosis. The disease causes dyspnea and progressive deterioration of lung function in patients with a poor prognosis and shorter survival time after diagnosis. Life expectancy of people with pulmonary fibrosis is generally less than five years. Median survival of 3–5 years has usually been reported a. The incidence and prevalence of idiopathic pulmonary fibrosis (IPF) is increasing worldwide. Pulmonary fibrosis is a progressive disease. This process gradually develops into irreversible fibrosis and can ultimately results in respiratory failure and death. The patients with pulmonary fibrosis suffer the physically afflicted and troubled in spirit.
However, treatment options for pulmonary fibrosis have been limited and ineffective. Clinically approved drugs are chemical drugs which have long course of treatment and can only slow down the deterioration rate without curing effects. So far there is no cure for pulmonary fibrosis. Therefore, tens of millions of patients are looking forward to the emergence of treatments that can reverse the course of pulmonary fibrosis. Lung transplantation may be an option. However, the risk of lung transplantation is extremely high and the number of donors is limited. Lots of complications occur during and at any time after the operation b. Although the stem cell treatment has recently emerged as a promising therapy for human diseases including lung fibrosis, the quality of stem cells cannot be controlled. The quality of stem cells is affected by many factors such as isolation, culture methods, and donors c. Furthermore, stem cell transplant patients may face immune rejection and complications; its clinical efficacy was not significant compared with expectations. Therefore, how to treat chronic pulmonary fibrosis has become an important topic in clinical medicine.
Since proteins play a key role in repairing injured tissue, protein drugs can follow the normal physiological operation mechanism to treat specific groups of people and cause fewer side effects. The R&D group of Pulmo BioMed has been deeply involved in the field of protein and peptides for many years. Based on the understanding of protein function and structure, we have successfully developed the new protein drug – PulmoHeal® with three advantages “reversal of pulmonary fibrosis, short-term therapy, and high safety". PulmoHeal® not only reverses the progression of pulmonary fibrosis but also helps pulmonary function and structure return to normal. Besides, the toxicological tests show that PulmoHeal® has excellent safety. It doesn’t have significant side effects like extreme weight-loss and organ damage. In summary, PulmoHeal® is a highly potential option for curing pulmonary fibrosis.
Clin Respir J. 2022 Feb; 16(2): 84–96.
Lancet Respir Med, 2019. 7(3): p. 271-282.
N Engl J Med. 2018 May 10;378(19):1811-1823.
Idiopathic pulmonary fibrosis (IPF), a specific form of chronic and progressive fibrosing interstitial pneumonia of unknown cause, is a common and typical type of pulmonary fibrosis. The disease causes dyspnea and progressive deterioration of lung function in patients with a poor prognosis and shorter survival time after diagnosis. Life expectancy of people with pulmonary fibrosis is generally less than five years. Median survival of 3–5 years has usually been reported a. The incidence and prevalence of idiopathic pulmonary fibrosis (IPF) is increasing worldwide. Pulmonary fibrosis is a progressive disease. This process gradually develops into irreversible fibrosis and can ultimately results in respiratory failure and death. The patients with pulmonary fibrosis suffer the physically afflicted and troubled in spirit.
However, treatment options for pulmonary fibrosis have been limited and ineffective. Clinically approved drugs are chemical drugs which have long course of treatment and can only slow down the deterioration rate without curing effects. So far there is no cure for pulmonary fibrosis. Therefore, tens of millions of patients are looking forward to the emergence of treatments that can reverse the course of pulmonary fibrosis. Lung transplantation may be an option. However, the risk of lung transplantation is extremely high and the number of donors is limited. Lots of complications occur during and at any time after the operation b. Although the stem cell treatment has recently emerged as a promising therapy for human diseases including lung fibrosis, the quality of stem cells cannot be controlled. The quality of stem cells is affected by many factors such as isolation, culture methods, and donors c. Furthermore, stem cell transplant patients may face immune rejection and complications; its clinical efficacy was not significant compared with expectations. Therefore, how to treat chronic pulmonary fibrosis has become an important topic in clinical medicine.
Since proteins play a key role in repairing injured tissue, protein drugs can follow the normal physiological operation mechanism to treat specific groups of people and cause fewer side effects. The R&D group of Pulmo BioMed has been deeply involved in the field of protein and peptides for many years. Based on the understanding of protein function and structure, we have successfully developed the new protein drug – PulmoHeal® with three advantages “reversal of pulmonary fibrosis, short-term therapy, and high safety". PulmoHeal® not only reverses the progression of pulmonary fibrosis but also helps pulmonary function and structure return to normal. Besides, the toxicological tests show that PulmoHeal® has excellent safety. It doesn’t have significant side effects like extreme weight-loss and organ damage. In summary, PulmoHeal® is a highly potential option for curing pulmonary fibrosis.
Clin Respir J. 2022 Feb; 16(2): 84–96.
Lancet Respir Med, 2019. 7(3): p. 271-282.
N Engl J Med. 2018 May 10;378(19):1811-1823.